Panel Discussion: Technology in Rare Disease Trials: Best Practices for Patient Centricity
Watch Now On-Demand
Rare Diseases have a significant medical footprint in society, and while most rare diseases might only affect a few hundreds to thousands of people worldwide, they are collectively common, affecting an estimated 25 million to 30 million people in the United States alone.Many of these diseases have a genetic cause, are serious or life-threatening and are hard to diagnose and treat. The U.S. Orphan Drug Act of the U.S. FDA has stimulated industry investment in clinical trials to develop treatments for rare diseases, yet only about 10% of rare diseases have an FDA-approved therapy for their treatment. Rare disease research poses challenges to investigators requiring specific approaches to the design of clinical studies; the discovery, testing, and approval of new treatments, and the training of patients and the medical community to improve access to diagnosis, research and treatments.
In this panel discussion, we sit down with experts in digital health, clinical research and patient engagement to discuss ways in which technology can address the challenges facing clinical development for rare disease.
Watch the panel discussion to learn:
- How does technology address challenges in the design and execution of clinical studies?
- What are the impacts of technology and decentralization on the integration of clinical research within the continuum of rare disease treatment, from diagnosis to treatment?
- How are partnerships with patients, caregivers and patient organizations changing the landscape of rare disease trials and registries?
Meet the Speakers
Grace Almendras-CastilloSVP, Digital Consumer Health, Alira Health and Founder, Self Care Catalysts, an Alira Health Company
Jared AdamsChief Product and Health Solutions Officer, Self Care Catalysts, an Alira Health Company
Kumara PalanivelDirector, Digital Medical Strategy, Alira Health
Renee WillmonSenior Director, Evidence and Outcomes, Self Care Catalysts, an Alira Health Company
TerSera Therapeutics to sponsor “NET Cancer Health Storylines” by Alira Health and Carcinoid Cancer Foundation to support patients suffering from Carcinoid Syndrome Diarrhea
We are pleased to announce TerSera Therapeutics’ sponsorship with the Carcinoid Cancer Foundation (CCF) and Alira Health to expand and optimize a holistic patient journey digital(...)
Alira Health Accelerates Global Growth and Secures Additional $58M Capital Injection
Alira Health, a global healthcare advisory, clinical research and technology company, announced it secured an additional US$58 million in capital funding, further strengthening its(...)
The Future of Healthcare: Patient-Owned Data
A revolution in patient data is upon us at long last...The future we envisioned then is now coming to fruition. This major paradigm shift puts data in the hands of patients, and we are ready for it.
Our Philosophy, Growth, and Future: An Interview with Gabriele Brambilla
In 2015, Alira Health was less than 30 people. Now, we are over 650 all across the world. We sat down with Gabrielle Brambilla, CEO of Alira Health, to find out more about the plan(...)
Outsourcing in Clinical Trials New England 2022
We are excited to share that we will be attending and exhibiting at Outsourcing in Clinical Trials New England in Boston.
HealthBiz Podcast: Interview with Gabriele Brambilla
Gabriele Brambilla, CEO of Alira Health, has joined the HealthBiz podcast to discuss how Alira Health strives to achieve its mission of humanizing healthcare, the importance of seeing(...)
Mobile Technology in Clinical Trials 2022
Join us at Mobile Tech in Clinical Trials, an event focusing on helping R&D operation executives support more patients remotely, including a demo of Health Storyline, our patient-driven(...)
Subscribe to our newsletter for the latest news, events, and thought leadership